Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Blodtryckssänkande strategier för att eliminera högt blodtrycksskillnader (VÄLSIGD) (BLESSED)

28 september 2026 uppdaterad av: Jiang He, MD, PhD, Tulane University

Blodtryckssänkande strategier för att eliminera skillnader i högt blodtryck

The burden of hypertension and related cardiovascular diseases, stroke, and end-stage kidney disease is disproportionately high in Black populations, especially in the South. The Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED) cluster randomized trial aims to test the effectiveness, implementation, and sustainability of a community health worker (CHW)-led multifaceted intervention compared to enhanced usual care for hypertension control in Black communities. In the BLESSED trial, the investigators plan to recruit 1,176 adults with hypertension (approximately 28 per church) from 42 predominantly Black churches in the Greater New Orleans area. The multifaceted intervention will last for 18 months, followed by a post-intervention follow-up visit at 24 months. The BLESSED trial aims to generate evidence regarding the effectiveness, implementation, and sustainability of this CHW-led church-based multifaceted intervention in eliminating hypertension disparities in the United States (US) general population.

Studieöversikt

Detaljerad beskrivning

Louisiana residents, especially African Americans, bear a disproportionately high burden of hypertension and cardiovascular disease (CVD). In the Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED) cluster randomized trial, the investigators will compare the impact of two implementation strategies - a CHW-led multifaceted strategy and a group-based education strategy - for delivering interventions recommended by the 2017 American College of Cardiology (ACC) and the American Heart Association (AHA) hypertension clinical guidelines on implementation and clinical effectiveness outcomes in predominantly Black community members over 18 months. The BLESSED study utilizes an effectiveness-implementation hybrid design to: (1). test the effectiveness of a CHW-led church-based multifaceted implementation strategy for reducing estimated CVD risk over 18 months among African American church community members at high risk for CVD, and (2). assess the implementation outcomes (acceptability, adaptation, adoption, feasibility, fidelity, penetrance, cost-effectiveness, and sustainability) simultaneously. The Exploration, Preparation, Implementation, Sustainment (EPIS) framework has guided the development and evaluation of the multifaceted implementation strategy, which includes CHW-led health coaching on lifestyle changes and medication adherence; healthcare delivery in community; church-based exercise and weight loss programs; self-monitoring of blood pressure (BP); and provider education and engagement. The CHW-led church-based intervention will provide strong social support and tackle multiple social determinants of CVD disparities. The primary clinical effectiveness outcome is the difference in mean change of systolic blood pressure (SBP) from baseline to 18 months between intervention and control groups. The primary implementation outcome is a fidelity summary score for key implementation strategy components to the CHW-led church-based multifaceted implementation strategy assessed at the participant levels. This study has 90% statistical power to detect group differences in mean SBP change of 5.8 mm Hg over 18 months using a 2-sided significance level of 0.05. The investigators will recruit 1,176 participants (28 per church) who are aged ≥18 years with systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥80 mm Hg, and randomly assign 21 churches to intervention and 21 to control; the investigators will implement the multifaceted intervention program; the investigators will follow-up participants and collect data on effectiveness and implementation outcomes at 6, 12, and 18 months; the investigators will evaluate the sustainability of the intervention at 6 months post-intervention; and the investigators will perform intention-to-treat analyses and disseminate and scale-up the proven-effective implementation strategy. The proposed study will generate evidence on the effectiveness, implementation, and sustainability of the multifaceted intervention aimed at eliminating CVD disparities in African American populations in the US.

Studietyp

Interventionell

Inskrivning (Beräknad)

1176

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Louisiana
      • New Orleans, Louisiana, Förenta staterna, 70112
        • Rekrytering
        • Tulane University
        • Kontakt:
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Men or women aged ≥18 years
  2. Community members associated with the participating churches (church members and their families and friends)
  3. Systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥80 mm Hg
  4. Willing and able to participate in the intervention.
  5. Willing and able to sign written informed consent.

Exclusion Criteria:

  1. Prior hospitalization in the last 3 months for chronic heart failure or heart attack
  2. Current diagnosis of cancer requiring chemotherapy or radiation therapy
  3. Stage-5 chronic kidney disease requiring chronic dialysis or transplant
  4. Pregnant or planning to become pregnant in the next 18 months
  5. Planning to move out of the Greater New Orleans area during the next year

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Förebyggande
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Enda

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Community health worker-led implementation strategy

CHW-led church-based multifaceted implementation strategy: CHWs will conduct individualized health coaching and healthcare navigation, organize church-based health promotion programs (e.g., nutrition education and exercise sessions), and train and assist the study participants in self-monitoring of BP. Nurse practitioners will see study participants at church settings, and community pharmacies will deliver antihypertensive medications to patients' homes.

The recommended evidence-based interventions include therapeutic lifestyle change and medical treatment of hypertension

Experimentell: Group-based Education Strategy

The investigator team will work with church leadership and wellness coordinators to organize group-based education sessions. Health education will be delivered by local primary care providers, dieticians, and health educators. Contact information for primary care providers and information on self-monitoring of BP will also be given at group sessions.

The recommended evidence-based interventions include therapeutic lifestyle change and medical treatment of hypertension

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Difference in mean change of systolic blood pressure
Tidsram: Measured from baseline to 18 months

Difference in mean change of systolic blood pressure from baseline to 18 months between intervention and control groups

Measured from baseline to 18 months
Implementation fidelity summary score
Tidsram: Measured at 6, 12, and 18 months

The fidelity summary score is composed of the following key implementation strategy components: proportion of assigned health education sessions attended in all participants, proportion of assigned discussion sessions attended in all participants, proportion of recommended minutes of physical activity completed in all participants, proportion of days per week that fruits/vegetables are eaten as recommended in all participants, proportion of recommended home blood pressure (BP) monitoring completed in patients with hypertension, proportion of required provider visits attended in all patients, and proportion of antihypertensive medications taken in patients with hypertension. The score ranged from zero to six with a higher score indicates greater fidelity.

Measured at 6, 12, and 18 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Difference in the proportion of patients with controlled BP between intervention and control groups
Tidsram: Measured from baseline to 18 months

Difference in the proportion of patients with controlled BP (<130/80 mm Hg) between intervention and control groups at 18 months

Measured from baseline to 18 months
Difference in mean change of diastolic BP
Tidsram: Measured from baseline to 18 months

Difference in mean change of diastolic BP (DBP) from baseline to 18 months between intervention and control groups

Measured from baseline to 18 months
Side effects of medications and adverse events
Tidsram: Measured from baseline to 18 months

Change in side effects of medications and adverse events from baseline to 18 months

Measured from baseline to 18 months
Cost-effectiveness
Tidsram: Measured from baseline to 18 months

Cost-effectiveness assessed as incremental direct costs per additional percentage of hypertension control

Measured from baseline to 18 months
Acceptability
Tidsram: Measured from baseline to 18 months

Percentage of participants, community health worker, providers, and church administrators who reply that the intervention is acceptable (satisfactory). Measured by survey.

Measured from baseline to 18 months
Adoption (Churches)
Tidsram: Measured from baseline to 18 months

% of churches adopting the intervention program

Measured from baseline to 18 months
Adoption (Providers)
Tidsram: Measured from baseline to 18 months

% of invited providers attending training sessions

Measured from baseline to 18 months
Appropriateness
Tidsram: Measured from baseline to 18 months

Percentage of participants, community health workers, providers, and church administrators who reply that the intervention is appropriate (good perceived fit). The outcome will be measured by survey question.

Measured from baseline to 18 months
Feasibility to participant, community health worker, provider and churches
Tidsram: Measured from baseline to 18 months

Percentage of participants, community health worker, providers, and church administrators who reply that the intervention is feasible (actual fit, suitability). Measured by survey and study administrative data.

Measured from baseline to 18 months
Exercise Session Fidelity (community health worker-led strategy group)
Tidsram: Measured at 6, 12, and 18 months

Percentage of exercise sessions organized. Measured by study administrative data.

Measured at 6, 12, and 18 months
Fidelity of Group Health Education Session
Tidsram: Measured at 6, 12, and 18 months

Percentage of group health education sessions conducted out of health educated sessions planned per study protocol.

Measured at 6, 12, and 18 months
Nutrition Education Session Fidelity (community health worker-led strategy group)
Tidsram: Measured at 6, 12, and 18 months

Percentage of nutrition education sessions organized. Measured by study administrative data.

Measured at 6, 12, and 18 months
Health Care Appointment Fidelity (community health worker-led strategy group)
Tidsram: Measured at 6, 12, and 18 months

Percentage of health care visit appointments made. Measured by study administrative data.

Measured at 6, 12, and 18 months
Percentage of enrolled participants receiving assigned intervention. Measured by study administrative data. Reach (Participants)
Tidsram: Measured at baseline, 6, 12, and 18 months

Percentage of enrolled participants receiving assigned intervention. Measured by study administrative data.

Measured at baseline, 6, 12, and 18 months
Reach (Participants)
Tidsram: Measured at baseline

The percentage of eligible/screened/contacted participants enrolled. Measured by study data, administrative data.

Measured at baseline
Penetrance (Participants)
Tidsram: Measured at baseline, 6, 12, and 18 months

Percentage of enrolled participants receiving assigned intervention. Measured by intervention monitoring data.

Measured at baseline, 6, 12, and 18 months
Penetrance (Providers)
Tidsram: Measured at baseline, 6, 12, and 18 months

Percentage of trained providers delivering protocol-based care. Measured by intervention monitoring data.

Measured at baseline, 6, 12, and 18 months
Penetrance (educators)
Tidsram: Measured at baseline, 6, 12, and 18 months

Percentage of trained CHWs or providers and health educators delivering health coaching. Measured by intervention monitoring data.

Measured at baseline, 6, 12, and 18 months
Sustainability (Churches)
Tidsram: Measured at baseline, 6, 12, and 18 months

Percentage of churches continuing the intervention program and individual components. Measured by 6-month post-intervention survey.

Measured at baseline, 6, 12, and 18 months
Sustainability (Participants)
Tidsram: Measured at 24 months

Percentage of participants maintaining ideal cardiovascular health metrics, healthy lifestyle components, and adherence to medications. Measured by 6-month post-intervention survey and examination.

Measured at 24 months
Sustainability Effectiveness Outcome: Differences in mean change of SBP and DBP
Tidsram: Measured at baseline and 24 months

Differences in mean change of SBP and DBP from baseline to 24 months (6 months post-intervention) between intervention and control groups

Measured at baseline and 24 months
Sustainability Effectiveness Outcome: Difference in the proportion of patients with controlled BP
Tidsram: Measured at baseline and 24 months

Difference in the proportion of patients with controlled BP (<130/80 mm Hg) between intervention and control groups at 24 months.

Measured at baseline and 24 months
Sustainability of Fidelity
Tidsram: Measured at 24 months

A fidelity summary score for key implementation strategy components at 6 months post-intervention (24 months overall). The fidelity summary score is composed of the following key implementation strategy components: proportion of assigned health education sessions attended in all participants, proportion of assigned discussion sessions attended in all participants, proportion of recommended minutes of physical activity completed in all participants, proportion of days per week that fruits/vegetables are eaten as recommended in all participants, proportion of recommended home BP monitoring completed in patients with hypertension, proportion of required provider visits attended in all patients, and proportion of antihypertensive medications taken in patients with hypertension. Fidelity score ranges from zero to six with a higher score indicates greater fidelity.

Measured at 24 months

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in quality of life
Tidsram: Measured from baseline to 18 months

The difference in QoL between the two arms over 18 months. QoL will be assessed using the SF-12 questionnaire. Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.

Measured from baseline to 18 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

1 november 2023

Primärt slutförande (Beräknad)

30 juni 2027

Avslutad studie (Beräknad)

30 juni 2027

Studieregistreringsdatum

Först inskickad

1 november 2023

Först inskickad som uppfyllde QC-kriterierna

10 november 2023

Första postat (Faktisk)

15 november 2023

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

1 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

28 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • 2022-1081-SPHTM
  • R01MD018193 (U.S.S. NIH-anslag/kontrakt)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

The study data sharing plan will comply with all NIH policies for data sharing. Data sharing will be executed through the centralized NIH data repository and will be implemented in a timely manner. The study data, including data from baseline and follow-up visits, will be prepared for transmission to the NHLBI data repository - the Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC). The datasets will be submitted to the NHLBI no later than three years after the end of the final participant follow-up or two years after the main paper of the trial has been published, whichever comes first. The NHLBI will review the submitted data prior to release. These data will be free of identifiers that allow identification of individual research participants either directly or through "deductive disclosure." In addition, the investigators will offer, through a publicly accessible website, opportunities for outside investigators to collaborate using complete study data.

Tidsram för IPD-delning

No later than three years after the end of the final participant follow-up or two years after the main paper of the trial has been published, whichever comes first

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • SAV

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera